Arrowhead Pharmaceuticals... (ARWR)
NASDAQ: ARWR
· Real-Time Price · USD
19.88
-0.03 (-0.15%)
At close: Aug 19, 2025, 3:59 PM
19.90
0.13%
After-hours: Aug 19, 2025, 06:42 PM EDT
-0.15% (1D)
| Bid | 19.8 |
| Market Cap | 2.75B |
| Revenue (ttm) | 545.21M |
| Net Income (ttm) | -143.97M |
| EPS (ttm) | -1.2 |
| PE Ratio (ttm) | -16.56 |
| Forward PE | -4.84 |
| Analyst | Buy |
| Ask | 20 |
| Volume | 1,437,919 |
| Avg. Volume (20D) | 1,947,258 |
| Open | 19.79 |
| Previous Close | 19.91 |
| Day's Range | 19.42 - 20.13 |
| 52-Week Range | 9.57 - 27.34 |
| Beta | 0.95 |
About ARWR
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ARWR
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ARWR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Arrowhead Pharmaceuticals Inc. is scheduled to release its earnings on
Nov 25, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
-1.53%
Arrowhead Pharmaceuticals shares are trading lower...
Unlock content with
Pro Subscription
3 weeks ago
+6.42%
Arrowhead Pharmaceuticals shares are trading higher after the company issued a statement reaffirming the strength of its exclusive license and collaboration agreement with Sarepta Therapeutics.
1 week ago · fool.com
Arrowhead (ARWR) Q3 Revenue Drops 41%Arrowhead (ARWR) Q3 Revenue Drops 41%
4 weeks ago · businesswire.com
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter ResultsPASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 7, 2025, at 4:30 p.m. ET to discus...
